B2BROKER
14.12.2021 11:02:59 CET | Business Wire | Press release
B2Broker , a leading technology and liquidity provider within the Forex/CFDs and Digital Currency industries, has confirmed that it has expanded its global reach by establishing a presence in the heavily EU regulated Forex /CFDs market through B2Prime , a Cyprus based Financial Institution authorised and regulated by the Cyprus Securities and Exchange Commission (CySEC).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211214005172/en/
B2Broker now has a vested interest in B2Prime after fulfilling the necessary legal requirements for the required ownership changes. The new owners of B2Prime are Arthur Azizov, founder of B2Broker Group of Companies and Evgeniya Mykulyak, co-founder of B2Broker Group of Companies. Nick Chrysochos becomes the CEO of B2Prime. The move confirms the group’s commitment to providing its investment related services on a global scale through a Liquidity Provider regulated by one of the most well respected and recognised Financial Market Supervisory Authorities.
About B2Prime
B2Prime is a global regulated Prime of Prime (PoP) Multi-Asset Liquidity Provider for institutional and professional clients across the whole spectrum of the financial markets. Its core investment services consist of leveraged derivative products in CFDs (Forex, metals, commodities, shares, indices and cryptocurrencies).
B2Broker Group of Companies
B2Broker is a global brand with a solid reputation in the B2B sphere as one of the most in-demand technology and liquidity providers for Forex and crypto brokers, crypto exchanges and other financial services entities. The company offers a wide range of services including Crypto/Forex/CFD liquidity, Crypto/Forex Broker turnkey solutions, crypto payment processing (B2BinPay), MT4/5 white label solutions, B2Core (Trader’s Room) , B2Trader (Matching Engine) and liquidity on over 800 trading instruments across the entire spectrum of assets.
Headquartered in Moscow, B2Broker has several years of operational experience with 10 offices in 8 countries across Russia, Europe, Asia and MENA. A total of 7 licences to its name including FCA, AEMI and Central Bank of Russia, allows B2Broker to serve clients across 50 countries, offering Forex liquidity distribution and a range of other services to the Forex, Crypto and Securities industries. The company has secured a large portfolio of well-known global clients in the financial services industry with plans to further increase company representation and visibility across the globe.
What the News Means For Clients
CySEC is Cyprus’ financial regulator which provides a framework within which the country’s licenced financial services firms are obliged to operate. As a CySEC regulated broker, B2Prime must adhere to the strictest financial market regulatory standards, including capital adequacy requirements, segregation of client funds and transparency of business operations.
Clients residing in the EU, UK and several other 3rd country jurisdictions can now be safely onboarded under the EU MiFID II regulatory standards. B2Broker can now expand its footprint in the European Union and provide clients with the opportunity to experience the organisation’s full product and service offering through an EU financial services brokerage licence, while positioning itself on an accelerated global growth path.
B2Broker Group of Companies CEO, Arthur Azizov, commented, “We are delighted that B2Prime has secured CySEC approval. The licence gives us the scope to provide institutional grade liquidity to clients in over 30 countries. Meanwhile, our clients will be able to benefit from an enhanced level of protection, safe in the knowledge that they have the backing of a world-leading, multi-regulated technology and liquidity provider. We expect that having now secured CySEC’s authorisation to provide our investment liquidity services, it will help us establish our place in this space as one of the strongest and most reliable organisations where clients can feel at ease when trading with us”.
B2Prime’s owner and Executive Director, Evgeniya Mykulyak, co-founder of B2Broker Group commented, “My vision is to make B2Prime one of the most solid and reliable financial services companies in the Forex space with a high standard of service provision being our key focus. I look forward to exploring the many new opportunities available to us in Europe and to welcoming new clients on board. Our efforts will include the introduction of new trading platforms for connection as well as the continued rollout of our Prime of Prime liquidity services. We are already building a strong liquidity provision network in the European market and have established relationships with major Prime Brokers. Furthermore, we plan to become a member of several exchanges, all in all, making B2Prime a major player in the financial services industry”.
B2Prime CEO, Nick Chrysochos added, “With Artur Azizov’s long experience and solid credentials in the Forex and Crypto space and Evgeniya Mykulyak’s deep industry know-how and clear vision for the company, we will be able to provide advanced, cutting-edge technology so that our clients can trade with the reassurance of knowing that their trading activities are managed by a reputable firm that adheres to the most stringent regulatory standards of CySEC”.
Final Word
BPrime has already opened the door to receiving new clients and can connect brokers via OneZero, MT5 and PrimeXM platforms to offer trading on 115 Forex pairs including 22 Crypto CFD pairs, Spot Metals, Indices and Spot Energies.
The latest licence acquisition is a part of B2Broker’s overall strategic plan to have a presence in all the major jurisdictions, focusing on the goal of becoming a global liquidity provider. The corresponding launch of commercial operations in Cyprus is also a testament to the company’s ongoing success and growth, where it will continue to provide some of the best liquidity and trading services in the industry.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211214005172/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom